In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Brought to you by

AZ to pay £567mm for Cambridge Antibody Technology

17 May 2006

Executive Summary

AstraZeneca has offered to pay £13.20 ($24.96) per share (a 72% premium to the market average) to buy the remaining 80% of Cambridge Antibody Technology Group PLC that it does not already own. It is effectively paying £567mm for the remaining stake, and valuing all of CAT at £702mm, about 4 times the company's 2005 revenues of £194mm.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Acquisition
    • Partial Acquisition
    • Payment Includes Cash

Related Companies

UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By